Delving into the Latest Updates on Baicalein with Synapse

Overview

Basic Info

Drug Type

Small molecule drug

Synonyms

Noroxylin, 黄芩素

Target

12/15-LOX x lipoxygenase

Action

inhibitors

Mechanism

12/15-LOX inhibitors(Arachidonate 15-lipoxygenase inhibitors), lipoxygenase inhibitors(Lipoxygenase inhibitors)

Therapeutic Areas

Nervous System DiseasesEndocrinology and Metabolic Disease

Active Indication

Parkinson Disease

Inactive Indication

FeverInfluenza, Human

Originator Organization

Jiangsu Kanion Pharmaceutical Co., Ltd.

Active Organization

Institute of Materia Medica

Inactive Organization

Jiangsu Kanion Pharmaceutical Co., Ltd.

CSPC Zhongqi Pharmaceutical Technology (Tianjin) Co., Ltd.

Chinese Academy of Medical Sciences

License Organization-

Drug Highest PhasePhase 1

First Approval Date-

RegulationSpecial Review Project (China)

Login to view timeline

Structure/Sequence

Molecular FormulaC15H10O5

InChIKeyFXNFHKRTJBSTCS-UHFFFAOYSA-N

CAS Registry491-67-8

Primary objective: To evaluate the safety and tolerability of multiple oral administration of 400 mg of Becryll chewable tablets in healthy elderly subjects under fasting conditions. Secondary objective: To evaluate the pharmacokinetic characteristics of multiple oral administration of 400 mg of Becryll chewable tablets in healthy elderly subjects under fasting conditions.

Start Date22 Apr 2021

Sponsor / Collaborator

Institute of Materia Medica

ChiCTR2000033286

/ CompletedNot ApplicableIIT

A Randomized, Double-blind, Placebo-controlled trial for determination of the Efficacy and Safety of Baicalein in Hospitalized Adult Mild and Moderate Patients of novel coronavirus pneumonia (COVID-19)

Start Date15 Feb 2020

Sponsor / Collaborator

Xiangyang Central Hospital

NCT03830684

/ Unknown statusPhase 2

A Randomized, Double-blind, Placebo-controlled, Multicenter and Phase Ⅱa Clinical Trial for the Effectiveness and Safety of Baicalein Tablets in the Treatment of Improve Other Aspects of Healthy Adult With Influenza Fever

This study in order to evaluate the Baicalein Tablets' safety and efficiency for audit with influenza

Start Date01 Feb 2019

Sponsor / Collaborator

CSPC Zhongqi Pharmaceutical Technology (Tianjin) Co., Ltd.

100 Clinical Results associated with Baicalein

Login to view more data

100 Translational Medicine associated with Baicalein

Login to view more data

100 Patents (Medical) associated with Baicalein

Login to view more data

6,425

Literatures (Medical) associated with Baicalein

31 Dec 2025·Artificial Cells, Nanomedicine, and Biotechnology

The integration of metabolites from Forsythia suspensa and gut microbiota ameliorates drug-induced liver injury: network pharmacology and molecular docking studies

Article

Author: Wang, Libo ; Wang, Jiabing ; Wang, Yanni ; Qian, Bingjie ; Peng, Xiangxiang

This study integrates metabolites from Forsythia suspensa (FS) and gut microbiota GM to assess combined therapeutic efficacy against drug-induced liver injury (DILI) using network pharmacology and molecular docking. Metabolites of FS and GM were retrieved from the NPASS and gutMGene databases, respectively. Relevant targets for metabolites and DILI-related targets were identified through public databases. The PPI network and KEGG pathway analysis were employed to identify hub targets and key signalling pathways. Furthermore, we performed a molecular docking assay on the active metabolites and targets to verify the network pharmacological concept. The physicochemical properties and toxicity of identified key metabolites were assessed using in silico platforms. 19 final targets were recognized as key proteins responsible for the alleviation of DILI by FS and GM metabolites, with ESR1 emerging as a central target in the PPI network. The estrogen signalling pathway, particularly involving ESR1, ESR2 and JUN genes, was identified as a key mediator in the therapeutic effects. Four GM metabolites (baicalein, luteolin, lunularin and 2,3-bis(3,4-dihydroxybenzyl)butyrolactone) and two FS metabolites (pinoresinol and isolariciresinol) were identified as non-toxic, promising candidates. In conclusion, metabolites from FS and GM may exert a potent synergistic effect on DILI through modulation of the estrogen signalling pathway.

31 Dec 2025·Pharmaceutical Biology

Antidepressant activity of flavones from traditional Chinese medicine: a meta-analysis

Review

Author: Wang, Qing ; Ma, Wei ; Mi, Xue ; Xia, Changbo ; Wang, Hanqing ; Yang, Caiyan ; Lu, Youyuan

CONTEXTFlavones, the key active components in Traditional Chinese Medicine (TCM), have demonstrated antidepressant activity. Given the numerous animal studies conducted, a systematic analysis is essential to provide a valuable reference for future research.OBJECTThis study investigated the antidepressant activity of flavones based on animal models and summarized the underlying mechanisms.METHODSWe systematically searched 7 bibliographic Databases as of August 12, 2023, such as Web of Science, PubMed, China National Knowledge Infrastructure, etc. The meta-analysis was performed using either the random or fixed-effect model, supplemented by trial sequential analysis (TSA). The Grading of Recommendations, Assessment, Development and Evaluations (GRADE) approach was used to assess the quality of evidence.RESULTSA total of 25 studies involving 458 mice were included, identifying five flavones (baicalin, baicalein, apigenin, luteolin, vitexin) with antidepressant activity. Compared to the control group, flavones significantly reduced immobility time in forced swimming and tail suspension tests. Flavones also decreased serum and hippocampal levels of interleukin (IL)-1β and tumor necrosis factor-alpha (TNF-α), reduced nuclear factor kappa B (NF-κB) levels, and increased brain-derived neurotrophic factor (BDNF) levels. Relative to the positive group, flavones raised IL-6, sucrose preference rate, and corticosterone (CORT) levels, with no significant differences in other factors. The TSA showed the efficacy of flavones for treating depression with adequate 'information size' for the primary outcome.CONCLUSIONSThe results demonstrate that flavones exert protective effects against depression in mice, primarily by stimulating neurotrophic factors and modulating inflammatory pathways. These findings emphasize their potential as promising candidates for the development of novel antidepressant therapies.

31 Dec 2025·Journal of Enzyme Inhibition and Medicinal Chemistry

Bioactivity profiling of Sanghuangporus lonicerinus : antioxidant, hypoglycaemic, and anticancer potential via in-vitro and in-silico approaches

Article

Author: Abdullaev, Ikram ; Petri, Edward ; Gafforov, Yusufjon ; Ghosh, Soumya ; Lim, Young Won ; Yarasheva, Manzura ; Rašeta, Milena ; Živanović, Nemanja ; Bekić, Sofija ; Chen, Jia Jia ; Abbasi, Arshad Mehmood ; Mišković, Jovana ; Wan-Mohtar, Wan Abd Al Qadr Imad ; Rapior, Sylvie ; Abdullaev, Bekhzod

This study investigates the mycochemical profile and biological activities of hydroethanolic (EtOH), chloroform (CHCl₃), and hot water (H₂O) extracts of Sanghuangporus lonicerinus from Uzbekistan. Antioxidant capacity was assessed using 2,2-diphenyl-1-picrylhydrazyl (DPPH), 2,2'-azino-bis-3-ethylbenzothiazoline-6-sulfonic acid (ABTS), NO, and FRAP assays, and in vitro hypoglycaemic effects were evaluated through α-amylase and α-glucosidase inhibition. Antiproliferative potential was explored by analysing the binding affinities of EtOH and H₂O extracts to estrogen receptor α (ERα), ERβ, androgen receptor (AR), and glucocorticoid receptor (GR), with molecular docking providing structural insights. LC-MS/MS analysis revealed solvent-dependent phenolic profiles, with the EtOH extract containing the highest total phenolic content (143.15 ± 6.70 mg GAE/g d.w.) and the best antioxidant capacity. The EtOH extract showed significant hypoglycaemic effects, with 85.29 ± 5.58% inhibition of α-glucosidase and 41.21 ± 0.79% inhibition of α-amylase. Moderate ERβ binding suggests potential for estrogen-mediated cancer therapy, while strong AKR1C3 inhibition by the EtOH extract supports its therapeutic potential.

100 Deals associated with Baicalein

Login to view more data

External Link

KEGG	Wiki	ATC	Drug Bank
-	-	-	DB16101

R&D Status

10 top R&D records.

Login

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Parkinson Disease	Phase 1	China	Institute of Materia Medica	11 Mar 2013
Fever	Discovery	-	CSPC Zhongqi Pharmaceutical Technology (Tianjin) Co., Ltd.	01 Feb 2019
Influenza, Human	Discovery	-	CSPC Zhongqi Pharmaceutical Technology (Tianjin) Co., Ltd.	01 Feb 2019
Parkinson Disease	Discovery	China	Jiangsu Kanion Pharmaceutical Co., Ltd.	11 Mar 2013

Login to view more data

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


AASLD2023	Not Applicable	Hepatocellular Carcinoma miR-5100 \| SMARCA2 \| JAK2-STAT3 signaling pathway	-	Baicalein	okdwmjzoah(fjnjmtjlsf) = ttvrlsabxk qtzatbeizq (uhxcjglxzd )	-	10 Nov 2023
FP287 (ERA2019)	Not Applicable	-	-	Cisplatin	(juodunkdyz) = pqdhvlcmhi oxstrslhie (xyuipbiyqr )	Positive	13 Jun 2019
FP287 (ERA2019)	Not Applicable	-	-	Cisplatin+Baicalein	(juodunkdyz) = vqwsqvxdyg oxstrslhie (xyuipbiyqr )	Positive	13 Jun 2019
ARVO2013	Not Applicable	-	9	Baicalein	(idxuryuxra) = ovusbauszy bsxpwsuzir (spaixagbfk, 0.89)	Positive	01 Jun 2013
ARVO2009	Not Applicable	-	-	Baicalein	(zglkbpbsbe) = yacmunyomm etqrlvegxz (wwdedwhbwo )	-	01 Apr 2009